Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Dong-A ST Co., Ltd.
  6. News
  7. Summary
    A170900   KR7170900005

DONG-A ST CO., LTD.

(A170900)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Neurobo Pharma Enters into Licensing Agreement with Dong-A ST

01/19/2018 EDT

Neurobo Pharmaceuticals Inc. has entered into licensing agreement with Dong-A ST Co Ltd. to develop and commercialize its herbal drug candidate DA-9801 for diabetic neuropathy. Under the agreement, Dong-A ST will received upfront payment of USD 2 million and a 5% stake in NeuroBo Pharma. In addition, NeuroBo Pharma agreed to pay Dong-A ST up to USD 178 million milestone payments and additional sales-tied royalties if the drug candidate clears clinical and commercial milestones. DA-9801 is a treatment for diabetic neuropathy. In 2011, the drug received support from the Ministry of Health and Welfare's healthcare research and development project.


© S&P Capital IQ 2018
All news about DONG-A ST CO., LTD.
07/22Intas Pharmaceuticals Limited Enters into an Exclusive License Agreement with Meiji and..
CI
02/08Dong-A ST Co., Ltd. Completes the Proof-Of-Concept Study for ‘DA-1241,’ an Investigatio..
CI
2020DONG-A ST CO., LTD.(KOSE : A170900) dropped from KOSPI 200 Index
CI
2019Dong-A ST and Beactica Therapeutics Achieve Key Milestone in Their Collaboration to Dev..
CI
2018Neurobo Pharma Enters into Licensing Agreement with Dong-A ST
CI
2017Dong-A and Pharmasyntez Consider Joint Venture for Russian Drug Manufacture
CI
2017Dong-A ST Co., Ltd. Enters into License Agreement with AbbVie, Inc
CI
2016ST Pharm Co.,Ltd. cancelled the acquisition of Banwol Factory from Dong-A ST Co., Ltd..
CI
More news
Financials
Sales 2021 584 B 0,50 B 0,50 B
Net income 2021 22,0 B 0,02 B 0,02 B
Net cash 2021 69,0 B 0,06 B 0,06 B
P/E ratio 2021 28,7x
Yield 2021 1,35%
Capitalization 626 B 533 M 532 M
EV / Sales 2021 0,95x
EV / Sales 2022 0,83x
Nbr of Employees 1 612
Free-Float 61,4%
Chart DONG-A ST CO., LTD.
Duration : Period :
Dong-A ST Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DONG-A ST CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 74 200,00 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Dae-Sik Eom Chief Executive Officer & Director
Hyeong-Heon Kim Head-Compliance Support
Geun-Soo Kim Independent Director
Jae-Sang Ryu Independent Director
Hui-Joo Choi Independent Director
Sector and Competitors